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ABSTRACT 
 
Mutations in avian influenza A viral hemagglutinin HA1 domain may alter the binding specificity of HA for 
α-sialosaccharide receptors, shifting the virus’s host range from birds to humans. The amino acid mutations 
can  occur  at  the sialoside  binding site,  as  well  as  the  antigenic  site,  far from  the  binding site.  Thus, a 
theoretical  study  involving  the  in  silico  prediction  of  HA-sialosaccharide  binding  may  require  quantum 
chemical analysis of HA1 full domain complexed with sialosides, balancing a computational cost with model 
size of HA1-sialoside complex. In addition, there is no insight to relationship between the model size of 
HA1-sialoside complex and its binding energy. In this study, H3 subtype HA1 full domains complexed with 
avian-  and  human-type  Neu5Acα(2-3  and  2-6)Gal  receptor  analogs  was  investigated  by  ab  initio  based 
fragment molecular orbital (FMO) method at the level of second-order Møller–Plesset perturbation (MP2)/6-
31G. Using this approach, we found avian H3 HA1 to bind to avian α2-3 receptor more strongly than to 
human α2-6 receptor in gas phase, by a value of 15.3-16.5 kcal/mol. This binding benefit was larger than that 
in the small model complex. Analysis of the interfragment interaction energies (IFIEs) between Neu5Ac-Gal 
receptor and amino acid residues on the full domain of H3 HA1 also confirmed the higher avian H3-avian 
α2-3 binding specificity. It was particularly important to evaluate the IFIEs of amino acid residues in a 13Å 
radius  around  Neu5Ac-Gal  to  take  account  of  long-range  electrostatic  interactions  in  the  larger  HA1-
sialoside complex  model. These results  suggest suitable size of HA1-sialoside complex is  significant to 
estimate HA1-sialoside binding energy and IFIE analysis with FMO method. 
 
KEYWORDS:  Virus  host  range,  sialosaccharide,  lectin, ab  initio,  FMO,  binding  energy,  interfragment 
interaction energy, second-order Møller–Plesset perturbation  
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INTRODUCTION 
 
Recent studies have revealed that binding specificities of 
influenza  viral  hemagglutinins(HA)  with  sialooligo-
saccharide receptors are involved in the virus host range 
determination  (Suzuki,  2005;  Matrosovich  et  al,  2006; 
Stevens et al, 2006a, Webster et al, 2006). Avian influenza 
viruses can bind to avian-type receptor Neu5Acα(2-3)Gal 
on human airway epithelium (Matrosovich et al, 2004) and 
lower respiratory tract (Shinya et al, 2006; van Riel et al, 
2006). However, this infection mechanism does not cause 
pandemic human influenza. We must pay attention to the 
higher  binding  affinity  of  avian  viruses  to  human-type 
receptor Neu5Acα(2-6)Gal (Shinya et al, 2005; Yamada et 
al, 2006; Chandrasekaran et al, 2008; Belser et al, 2008, 
Steavens  et  al,  2008).  When  the  binding  specificity  of 
mutant  influenza  viral  HA  with  human  α2-6  ligand  is 
predicted  in  advance,  we  can  take  measures  against  an 
outbreak  of  pandemic  human  influenza.  However,  a 
scientific framework for studies to predict changes in the 
host  ranges  of  influenza  viruses  has  not  yet  been 
established.  We  believe that, with  high performance PC 
cluster, ab initio based fragment molecular orbital (FMO) 
studies of the HA-sialoside complexes will help to predict 
the chemical properties of HA-sialoside binding (Sawada 
et al, 2006, 2007, 2008; Iwata et al, 2008). 
 
Influenza  virion  attaches  to  α-sialoglycoproteins  and  α-
sialoglycolipids  on  the  host  cell  surface  via  molecular 
interactions between the viral HA and sialooligosaccharide 
(Böttcher et al, 1999; Horimoto and Kawaoka, 2005). HA 
forms a trimer which has sialoside receptor binding sites on 
the surface of each HA1 domain (Skehel and Wiley, 2000). 
The binding site consists of 130-loop, 150-loop, 190-helix, 
and  220-loop, and  their  chemical  behaviours  allow  avian 
viral HA to interact specifically with the avian Neu5Acα(2-
3)Gal receptor (Ha et al, 2001, 2003; Gamblin et al, 2004; 
Stevens et al, 2004, 2006b; Russell et al, 2006). Amino acid 
substitutions  at  the  sialoside  binding  site  change  HA-
sialoside binding properties (Lin and Cannon, 2002; Glaser 
et  al,  2005;  Yamada  et  al,  2006;  Tumpey  et  al,  2007; 
Auewarakul et al, 2007; Yang et al, 2007). In addition, a 
substitution at HA1 antigenic site D, which is situated far 
from  the  sialoside  binding  site,  also  alters  the  relative 
binding specificity of HA with human/avian-type receptors 
(Suzuki et al, 1989). These results suggest that mutations on 
avian viral HA1 can shift the host range of virus from birds 
to  humans,  therefore,  chemical  prediction  studies  may 
require quantum chemical analyses of sialoside receptors in 
complex with the entire HA1 domain. At the same time, we 
should  balance  a  computational  cost  with  model  size  of 
HA1-sialoside complex. However, there is no insight into 
relationship  between  the  model  size  of  HA1-sialoside 
complex and its binding energy. 
 
We  previously  reported  the  binding  energies  and 
interfragment  stabilizations  between  avian  H3  and 
disaccharide  analogs  of  avian-  and  human-type 
Neu5Acα(2-3 and 2-6)Gal receptors (Sawada et al, 2008). 
In  these  study,  we  used  small  model  complex  of  the 
binding  site  (70  amino  acids)  and  conducted  FMO 
calculations  at  the  MP2/6-31G  level  to  evaluate  the 
intermolecular  electrostatic  interactions  and  dispersion 
interactions.  However,  this  approach  had  to  treat 
sensitively the peptide terminals in the very small binding 
site  models.  Recently,  with  a  suitable  PC  cluster,  FMO 
method  was  shown  to  calculate  a  viral  HA-antibody 
complexes at the MP2 level (Mochizuki et al, 2008), as 
well as HA1 full domain-sialoside complexes. 
  
In  the  FMO  two-body  terms  method  (FMO2),  an  HA1-
sialoside  complex  is  divided  into  N  fragments,  and 
molecular  orbital  calculations  are  carried  out  on  each 
fragment (I, J,..,  N)  and  fragment  pairs  (IJ,  IK,  IL,...,JK, 
JL,…, (N-1)N). Next, the total energy E of the entire HA1-
sialoside complex is evaluated with the following equation: 
 
 N   N 
E = Σ EI + Σ (EIJ – EI – EJ) 
I  I>J 
 
where  the  terms  represent  summation  of  the  fragment 
energies  and  interfragment  interaction  energies  (IFIEs), 
respectively (Kitaura et al, 1999a,b). 
 
Since  the  method  estimates  IFIEs  by  taking  account  of 
many-body corrections (Yamamoto et al, 2006; Yamagishi 
et  al,  2006),  we  are  able  to  analyze  intermolecular 
stabilizations  of  Neu5Ac-Gal  receptors  with  amino  acid 
residues at the sialoside binding site on HA1. 
 
In this study, we applied FMO method to influenza viral 
HA  H3-subtype  HA1  full  domain  complexed  with  the 
avian-  and  the  human-type  Neu5Acα(2-3  and  2-6)Gal 
disaccharides.  Binding  energies  between  HA1s  and 
sialosides were computed at the FMO2-MP2/6-31G level. 
We analyzed relationships between HA1-siaoside binding 
energies and size-dependency of HA1-siaoside complexes. 
Besides  interfragment  stabilizations  in  the  two  kinds  of 
larger  HA1  complexes  were  compared  to  give  some 
guidance for future large-scale FMO studies. 
 
MATERIALS AND METHODS 
 
Computational analysis 
The  H3-receptor  complexes  for  the  FMO  studies  were 
obtained from the energy minimum structures of avian and 
human  A  virus  H3-subtype  trimers  in  complex  with 
Neu5Acα(2-3  or  2-6)Gal  analogs as  reported  previously 
(Sawada et al, 2008). We clipped small model complex A, 
large-size complex B, and full-size HA1 complex C from 
the  geometry  optimized  avian/human  H3  complexes 
(Figure 1). Peptide terminals in the models were treated as 
NH3
+ and COO
- in a similar manner to that used in our 
previous studies. We computed the single point energies of 
the whole complexes (Ecomplex), corresponding to H3 HA1 
domains  (EH3),  and  Neu5Acα(2-3/6)Gal  (Ereceptor)  at  the 
FMO2-MP2/6-31G level, followed by evaluation of H3-
sialoside binding energy (∆E) by the following equation: 
 
∆E = (EH3＋Ereceptor) – Ecomplex 
 
The  HA1  domains  were  divided  into  single  amino  acid 
residue as a single fragment (with the exception of Cys S-
S  Cys  pairs)  using  automatic  fragmentation  scheme  in  
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ABINIT-MP  package  (http://www.ciss.iis.u-tokyo.ac.jp 
/fsis/en/index.html)  (Figure  2).  Neu5Ac-Gal  receptors 
were treated as a single fragment charged to −1 (Figure 3). 
To compute neutral H3–sialoside system in gas phase, H3 
HA1 domains in the complexes A-C were charged to +1 as 
same manner in our previous studies (Sawada et al, 2006, 
2007, 2008), namely several δ-guanidium on Arg and ε-
ammonium on Lys were de-protonated to be neutral form 
(Table  1).  FMO  calculations  were  carried  out  using 
ABINIT-MP program. 
 
 
 
 
 
Figure 1. The complexes of inﬂuenza A virus H3 HA1 domain 
with Neu5Ac-Gal analog for the FMO-MP2/6-31G calculations.  
A. The complex has the smallest receptor binding site (Sawada et 
al, 2006, 2008). The site has four peptides Asn96-Pro99, Gly129-
Tyr161, Gly181-Val196, and Asn216-Ile232 to be total 70 amino 
acids. B. Binding domain in the complex consists of Arg(Ile)62-
Gly263 (202 amino acids, avian H3; Arg62, human H3; Ile62), 
C. The complex has the full size of HA1 domain (avian H3; 
Ser9-Lys326, human H3; Gln1-Thr328, Sawada et al, 2007). 
ribbon model; HA1, red; helix, blue; sheet, CPK model; 
Neu5Ac-Gal analog. 
 
 
 
 
 
 
 
Figure 2. Schematic fragmentation of H3 HA1 domain. HA1 
domain was fragmented by cutting Cα-C bonds in accordance 
with general manner (Fedorov and Kitaura, 2006). Cα were bond 
detached atoms. Fragment 1, 2,..., i, i+1,…, N were treated as 
amino acid residue 1, 2,…, i, i+1,…, N. 
 
 
 
 
Figure 3. Schematic structures of avian and human receptor 
Neu5Acα(2-3 and 2-6)Gal 
 
 
RESULTS AND DISCUSSION 
 
Binding energies between HA1 and Neu5Acα(2-3 and 
2-6)Gal receptors 
Binding  energies  (∆Es)  of  the  avian  and  human  H3 
complexes  B,  C  at  the  FMO-MP2/6-31G  level  are 
summarized in Tables 2 and 3. Avian H3 bound to avian 
receptor  Neu5Acα(2-3)Gal  stronger  than  to  human 
receptor  Neu5Acα(2-6)Gal  by  a  value  of  15.3-16.5 
kcal/mol (Table 2; entries 8, 9). 
 
∆Es of the larger avian H3 complexes B and C have 14.5-
24.1 kcal/mol larger values than those of small complex A 
(Table 2; entries 2, 3, 5, 6) because the former two models 
take  into  account  long-range  electrostatic  interactions 
between  Neu5Ac-Gal  and  charged  amino  acid  residues. 
With  the  long-range  interaction,  energy  difference 
between ∆Eα2-3 and ∆Eα2-6 are 15.3 and 16.5 kcal/mol in 
the models B and C (Table 2; entries 8, 9). These results 
suggest  that  model  B  has  enough  size  for  the  binding 
energy calculation at the FMO-MP2 level. Consideration 
of more real HA trimer-sialoside system, trimerized model 
B may give an accurate binding energy with FMO method. 
Model B involves antigenic sites A, B, D, and E (Smith et 
al, 2004). 
 
In the human H3–human α2-6 complex, full model C has a 
highest ∆Eα2-6 203.1 kcal/mol, which is about 50 and 36 
kcal/mol larger than those of models A and B (Table 3; 
entries  1-3).  In  addition,  energy  difference  in  ∆Eα2-6 
between human H3 complex A and B (Table 3; entries 1, 
2)  is  15-16  kcal/mol  larger  than  the  corresponding 
differences in the avian H3 complexes (Table 2; entries 4, 
5. Table 3; entries 4, 5). These data indicate that human 
H3  differs  from  avian  H3  in  terms  of  the  relationship 
between  ∆Eα2-6  and  model  structure,  whose  details  are 
discussed by IFIE analysis in  next section.  Here  we  note   
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Table 1: Basic and acidic amino acid residues in the models A-C 
   
H3  model  Arg  Lys  His
*4  terminal NH3
+  Asp  Glu  ternimal 
COO
- 
Avian  A
*1 
141
*3, 150
*3, 
220, 224
*3, 
229
*3 
140, 156   183(E), 184(E)  Asn96, Gly129, 
Gly181, Asn216 
  158, 190  Pro99, 
Tyr161, 
Val196, 
Ile232 
                 
  B 
62
*3, 90, 
109, 141, 
150, 201, 
207, 208
*3, 
220, 224, 
229, 255, 
261 
140, 156, 
176, 238, 
259 
75(E), 183(E), 
184(E) 
Arg62  68, 73, 77, 
85, 101, 104, 
172, 175, 
241 
82, 89, 
119, 123, 
158, 190 
Gly263 
                 
  C 
57,62
*3, 90, 
109, 141, 
150, 201, 
207, 208
*3, 
220, 224, 
229, 255, 
261, 269
*3, 
321 
27, 50, 
140, 156, 
176, 238, 
259, 264, 
292, 299, 
307, 310, 
315, 326
*3 
17(E), 18(E), 
56(E), 75(E), 
183(E), 184(E) 
Ser9  31, 32, 60, 
68, 73, 77, 
85, 191, 104, 
172, 175, 
241, 271, 
275, 291 
35, 41, 82, 
89, 119, 
123, 158, 
190, 280, 
325 
Lys326 
Human  A
*1 
141
*3, 150, 
220
*3, 224
*3, 
229
*3 
140, 156
*3  183(E), 184(E)  Asn96, Gly129, 
Gly181, Asn216 
  190  Pro99, 
Tyr161, 
Val196, 
Ile232 
                 
  B
*2 
90, 109, 141, 
150, 201, 
207, 208, 
220, 224, 
229, 255, 
261
*3 
92
*3, 140, 
156, 176, 
238, 259
*3 
75(P), 183(E), 
184(E) 
Ile62  63, 68, 73, 
77, 85, 101, 
104, 172, 
175, 241 
82, 89, 
119, 123, 
190 
Gly263 
                 
  C
*2 
57, 90, 109, 
141, 150, 
201, 207, 
208, 220, 
224, 229, 
255, 261
*3, 
269
*3, 321
*3 
27, 50, 92, 
140, 156, 
176, 238, 
259, 264, 
292, 299, 
307, 310, 
315, 326 
17(D), 18(E), 
56(E), 75(P), 
183(E), 184(E) 
Gln1  2, 7, 31, 32, 
60, 63, 68, 
73, 77, 85, 
101, 104, 
172, 175, 
241, 271, 
275, 291 
35, 41, 82, 
89, 119, 
123, 190, 
280, 325 
Thr328 
 
*1 Sawada et al, 2006, 2008 
*2 Sawada et al, 2007 
*3 Side chain δ-guanidium on Arg and ε-ammonium on Lys are neutralized in order to compute neutral H3–sialoside complex. 
*4 There are three types of histidine. E; neutral form with NE proton. D; neutral form with ND proton. P; positive charged form with 
ND and NE protons. 
 
 
 
 
that  monotonous  increase  of  ∆Eα2-6  in  the  human  H3 
complex  is  probably  a  pretense  (Table  3;  entries  1-3) 
because the ∆Eα2-6 does not simply increase at the FMO-
RHF/STO-3G level as the model complex became larger 
(Sawada et al, 2007). 
 
Gln226Leu substitution on avian H3 changes the binding 
specificity from avian α2-3 to human α2-6 (Rogers et al, 
1985).  In  the  smallest  model  A,  ∆Eα2-6  of  avian 
Gln226Leu H3 complex is quite similar to that of human 
H3 complex (Table 3; entries 1, 4. Sawada et al, 2008). 
However, the similarity is lost as the model size becomes 
larger  (Table  3;  entries  2,  3,  5,  6).  Their  details  are 
discussed by IFIE analysis in next section. 
 
In this section, we have analyzed a relationship between 
HA1-siaoside  binding  energy  in  gas  phase  and  size-
dependency of HA1-siaoside complex with charged amino 
acid residues. Avian H3 HA1 binds to avian α2-3 receptor 
15.3-16.5  kcal/mol  more  strongly  than  to  human  α2-6 
receptor in gas phase, and this binding benefit  is larger 
than  corresponding  in  small  model  complex.  Avian  H3 
HA1 differs from human H3 in terms of the relationship 
between  ∆Eα2-6  and   model  structure.   To  obtain   more   
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Table 2. Binding energies in kcal/mol of avian H3 with 
avian/human Neu5Acα(2-3/6)Gal receptors 
 
Entry    Model  MP2/6-31G 
1  ∆Eα2-3  A  180.4
*1 
2    B  204.5 
3    C  200.0 
       
4  ∆Eα2-6  A  169.0
*1 
5    B  189.2 
6    C  183.5 
       
7  ∆Eα2-3-∆Eα2-6  A  11.4
*1 
8    B  15.3 
9    C  16.5 
 
*1 These data were previously reported in Sawada et al (2008). 
 
 
 
Table 3. Binding energies in kcal/mol of human and avian 
Gln226Leu H3s with human Neu5Acα(2-6)Gal receptors 
 
      ∆Eα2-6 
Entry  H3  Model  MP2/6-31G 
1  Human  A  154.3
*1 
2    B  190.2 
3    C  203.1 
       
4 
Avian 
Gln226Leu  A  157.6
*1 
5    B  177.4 
6    C  172.3 
 
*1 These data were previously reported in Sawada et al (2008). 
 
 
accurate  total  energies  and  binding  energies  of  HA1-
sialoside  complexes,  we  will  apply  the  following 
approaches in the near future: [a] Fragmentation of HA1 
domain into larger blocks, e.g., two amino acid residues as 
a fragment (Nemoto et al, 2005; Fukuzawa et al,  2006; 
Nakanishi et al, 2007), [b] Applying larger basis sets, such 
as 6-31(+)G(d), where diffuse function was added on the 
negative charged groups COO
-, [c] Correlation of basis set 
superposition  error,  [d]  QM/MM  or  multilayer  FMO 
(Fedorov  et  al,  2005)  geometry  optimization  of  HA1-
sialoside  complex  with  explicit  water  solvent  after 
structural  equilibrations  are  carried  out  by  molecular 
dynamics  simulations,  [e]  Utilizing  more  approvable 
expressions to calculate the binding energy of protein with 
ligand  (Nemoto  et  al,  2005;  Nakanishi  et  al,  2007),  [f] 
Major part of larger binding energy in gas phase should be 
correlated by de-solvation enegy (Nakanishi et al, 2007). 
 
Mainly, binding free energy of HA to sialoside in aqueous 
phase governs HA-sialoside binding affinity (Chong et al, 
1999;  Pathiaseril  and  Woods,  2000;  Leach,  2001).  To 
evaluate  the  binding  free  energy,  many  elements  in  the 
thermodynamic cycle of binding free energy are calculated 
by  using  various  approximations  and  computational 
methods (Nakanishi et al, 2007). FMO-MP2 calculations 
can  provide  enthalpic  energies  of  the  HA-sialoside 
complex,  isolated  HA,  and  sialoside  receptor  as  some 
elements  in  the  thermodynamic  cycle.  However,  for  in 
silico  predictions  of  the  avian  HA  mutant-human  α2-6 
binding, we require a simple and qualitative framework. 
 
In  order  to  establish  the  appropriate  framework,  we 
propose a trial such that in silico simulations are utilized to 
estimate various kinds of differences (∆ values) between 
the original avian HA-human α2-6 binding (control) and 
HA mutant-human α2-6 bindings, where ∆ values are e.g., 
relative binding energies of HA mutants to α2-6 ligand, 
relative  interfragment  stabilizations,  and  relative 
flexibilities of HA mutant-human α2-6 complexes. Since 
recent  experimental  studies  have  revealed  binding 
properties of original avian HA and its mutants to human 
α2-6 receptor, in silico simulation of the reported avian 
HA-human α2-6 systems will afford a reliable relationship 
between ∆ values and mutation positions on HA1 domain. 
This approach avoids computing the binding free energy. 
Instead,  we  need  to  adopt  chemical  intuition  to  select 
suitable  ∆  values.  The  ∆  values  should  satisfy  some 
requirements,  such  as  approximate  independence  each 
other,  relation  to  the  binding  free  energy,  and  needless 
large-sized sampling.  In the future, we will  develop the 
concept,  and  attempt  to  find  the  ∆  values  using  MD 
simulation, QM/MM calculation, and FMO-MP2 studies.  
 
Analysis of interfragment interaction energies between 
Neu5Acα(2-3 and 2-6)Gal and amino acids on HA1 
In the above section, we have mentioned that human H3 
differs from avian H3 in terms of the relationship between 
∆Eα2-6 and model structure (Table 2; entries 4, 5, Table 3; 
entries  1,  2),  besides  there  is  no  similarity  of  ∆Eα2-6 
between  human  Leu226  H3  complex  and  avian 
Gln226Leu H3 complex in the model B (Table 3). These 
results  are  explained  by  analysis  of  IFIEs  between 
Neu5Acα(2-6)Gal and amino acid residues on H3 in the 
models A and B (Table 4). Charged amino acid residues 
strongly  interacts  with  negative  charged  Neu5Acα(2-
6)Gal,  and  whose  interaction  energies  affect  the  human 
α2-6-H3  binding  energy.  Since  expanding  model  size 
from complex A to B with neutral HA-sialoside system 
demands us to de-protonate and re-protonate amino acid 
side chain δ-guanidium on Arg and ε-ammonium on Lys, 
modification of model A range in the human H3 model B 
quite differs from that of avian H3 complex (Table 1; lines 
Arg and Lys). Thus, in terms of the relationship between 
∆Eα2-6  and  model  structure,  human  H3  has  a  different 
tendency  from  the  corresponding  avian  H3  (Table  4; 
entries  9,  12).  Avian  Gln226Leu  H3  has  the  same 
tendency  as  avian  Gln226  H3  that  causes  the  non-
similarity of ∆Eα2-6 between avian Gln226 H3 and human 
Leu226 H3. Comparing amino acid sequence of avian H3 
with human H3 shows four substitutions at 62, 63, 92, and 
102 on the model B range excluding the range of model A 
(Figure 4), then the charged residues affect H3-sialoside 
binding  energies  (Table  4;  entry  14).  Expanding  model 
size from B to C decreases the ∆Eα2-6 by ~5.1-5.7 kcal/mol  
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Table 4. The sums of IFIEs between human Neu5Acα(2-6)Gal with amino acid residues on avian and human H3 in the models A and 
B at the FMO-MP2/6-31G level 
 
      sum of IFIEs (kcal/mol) 
Entry    amino acid residues  avian H3  human H3 
1  model A  substituted residues (non-charge)
*1  70.6  72.3 
2    substituted residues (charge)
*2  -16.7  1.2 
3    Arg, Lys, His(P), Asp, Glu
*3  71.2  40.2 
4    terminal residues
*4  2.6  0.3 
5    others  108.1  105.9 
6    total  235.8  219.9 
         
  model B  model A range in model B     
7    substituted residues (non-charge)
*1  69.2(-1.4)
*10  70.3(-2.0)
*10 
8    substituted residues (charge)
*2  -16.8(-0.1)  1.2(0.0) 
9    Arg, Lys, His(P), Asp, Glu
*5  156.8(85.6)  158.3(118.1) 
10    terminal residues
*6  6.3(3.7)  4.4(4.1) 
11    others  79.3(-28.8)  73.7(-32.2) 
12    total  294.8(59.0)  307.9(88.0) 
         
    model B range excluding model A     
13    substituted residues (non-charge)
*7  -0.2  -0.3 
14    substituted residues (charge)
*8  0.4  -14.6 
15    Arg, Lys, His(P), Asp, Glu
*5  -67.4  -62.5 
16    terminal residues
*9  4.2  4.1 
17    others  3.8  1.5 
18    total  -59.2  -71.8 
         
19    model B total (entry 12+18)  235.6  236.1 
 
*1 amino acid positions are 137, 144, 145, 160, 182, 193, 226, 227, and 228 
*2 amino acid position is 158 
*3 their form are shown in table 1; model A 
*4 N- and C-terminal residues are charged +1 and -1, respectively (table 1; model A) 
*5 their form are shown in table 1; model B 
*6 the residues do not charged because they are parts of peptide chain in model B. 
*7 amino acid position is 102 
*8 amino acid positions are 63 and 92 
*9 N- and C-terminal residues are 62 and 263 as shown in table 1; model B 
*10 values in parenthesis are given by [model A]-[model A range in model B]  
 
 
 
 
in the avian H3 complexes (Tables 2, 3; entries 5, 6), but 
increases 13.1 kcal/mol in human H3 complex (Table 3; 
entries  2,  3).  These  results  are  mainly  caused  by 
interfragment  long-range  electrostatic  interactions  of 
Neu5Ac-Gal with charged amino acid residues. 
 
Changing  the  aspects  of  IFIEs  analysis  gives  some 
guidance how much range (Å) around Neu5Ac-Gal analog 
in the gas phase HA1 complex is significant to evaluate 
sialsoside-HA1  interaction.  The  sums  of  interfragment 
interaction energies (s-IFIEs) between Neu5Acα(2-3 and 
2-6)Gal and amino acid residues in the models B and C at 
the  FMO-MP2/6-31G  level  are summarized  in  Tables  5 
and 6. s-IFIEs of amino acid residues within a 13Å radius 
around Neu5Ac-Gal were 41 to 43 kcal/mol larger than the 
s-IFIEs in model A range in the avian H3 complex (Table 
5; entries 1 and 2, 5 and 6, Table 6; entries 11 and 12, 15 
and  16),  24  kcal/mol  larger  in  the  human  H3  complex 
(Table 5; entries 1 and 2, 5 and 6). Thus, model A is too 
small to evaluate the intermolecular stabilization. In our 
study,  Neu5Ac-Gal  analogs  are  charged  –1,  which 
strongly interacts with amino acids residues in 13Å radius 
around  Neu5Ac-Gal  by  interfragment  long-range 
electrostatic interactions. As some common factors in the 
partial  model  B  and  full  model  C,  s-IFIEs  within  13Å 
radius around Neu5Ac-Gal give similar values 358.4 and 
357.3 kcal/mol in the avian H3-avian α2-3 complex (Table 
5; entries 2, 6), 331.2 and 332.0 kcal/mol in the human 
H3-human 2-6 complex (Table 6; entries 2, 6), 324.8 and 
323.7  kcal/mol in the avian  Gln226Leu H3-human α2-6 
complex (Table 6; entries 12, 16). Besides, the addition of 
IFIEs  in  charged  amino  acids  to  the s-IFIEs of the 13Å   
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Table 5. Sum of IFIEs between avian/human Neu5Acα(2-3 and 2-6)Gal and amino acid residues on avian H3 models B and C at the 
FMO-MP2/6-31G level 
 
        Sum of IFIEs in kcal/mol 
Entry  H3  model  amino acid residues  avian α2-3  human α2-6  ∆
*1 
1 Avian  B  model A
*2  317.5  294.8  22.7 
2     13Å
*3  358.4  337.2  21.2 
3     13Å + charged residues
*4  260.4  237.0  23.4 
4     all (Arg62-Gly263)  258.6  235.6  23.0 
             
5   C  model A
*2  316.4  293.7  22.7 
6     13Å
*3  357.3  336.1  21.2 
7     13Å + charged residues
*4  251.9  227.8  24.1 
8     model B (Arg62-Gly263)  253.7  230.7  23.0 
9     all (Ser9-Lys326)  252.5  228.7  23.8 
 
*1 ∆ represents [sum of IFIEs between avian α2-3 and amino acids]−[sum of IFIEs between human α2-6 and amino acids]. 
*2 model A consists of 70 amino acid residues (Asn96-Pro99, Gly129-Tyr161, Gly181-Val196, Asn216-Ile232, Figure 5) 
*3 Amino acid residues within 13Å radius around Neu5Ac-Gal are Pro74, Asn96-Pro99, Val130-Ser157, Tyr161, Leu164, Gly181-
Gln197, Asn216-Pro221, Val223-Ile232, Asn250-Ala253, and Arg255. 
*4 Charged residues are listed in table 1 
 
 
 
 
 
 
 
Table 6. Sum of IFIEs between human Neu5Acα(2-6)Gal and amino acid residues on human Leu226 and avian Gln226Leu H3 
models B and C at the FMO-MP2/6-31G level 
 
Entry  H3  Model  amino acid residues  human α2-6 
1 Human  B  model A  307.9 
2     13Å   331.2 
3     13Å + charged residues  238.9 
4     all(Ile62-Gly263)  236.1 
         
5   C  model A  308.5 
6     13Å   332.0 
7     13Å + charged residues  248.2 
8     model B (Ile62-Gly263)  254.8 
9     Ser9-Lys326  255.0 
10     all(Gln1-Thr328)  248.1 
         
11 Aian Gln226Leu  B  model A  282.4 
12     13Å   324.8 
13     13Å + charged residues  224.2 
14     all(Arg62-Gly263)  222.4 
         
15   C  model A  281.2 
16     13Å   323.7 
17     13Å + charged residues  215.6 
18     Arg62-Gly263  217.5 
19     all(Ser9-Lys326)  216.1  
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Figure 4. Sequence alignments of avian and human H3 HA1 in the model complexes A, B, and C: Yellow; non-matching residue, 
green; weak matching residues, light blue; strong matching residue, brown; smallest binding site in the model A, purple; difference in 
the model B and C. 
 
 
 
 
radius residues affords similar values to the corresponding 
s-IFIEs of all amino acids (Table 5; entries 3 and 4, 7 and 
9, Table 6; entries 3 and 4, 7 and 10, 13 and 14, 17 and 
19).  In the full model C, the s-IFIEs of all amino acid 
residues  are  almost  same  with  that  of  model  B  range 
(Table 5; entries 8, 9. Table 6; entries 8 and 9, 18 and 19). 
These results suggest that adequate IFIE analysis requires 
the amino acids in a 13Å radius around Neu5Ac-Gal in 
model  B.  In  the  human  H3  model  C,  negative  charged 
Asp2 and 7 un-stablize the complex to give slightly lower 
s-IFIEs  248.1  kcal/mol  than  s-IFIEs  of  Ser9-Lys326 
(Table 6; entries 9, 10). 
 
Our  IFIE analysis  in  the larger  models  B  and C at  the 
FMO-MP2/6-31G level confirms that avian H3 interacts 
with  avian  α2-3  receptor  at  21  to  24  kcal/mol  more 
strongly than with the human α2-6 receptor (Table 5; line 
∆). In the previous study, s-IFIEs of thirteen amino acid 
residues in the avian H3-avian α2-3 complex A is about 10 
kcal/mol larger than that of avian H3-human α2-6 complex 
with  a  sensitive  treatment  of  various  charged  residues 
(Sawada et al. 2008). Thus we should evaluate the s-IFIEs 
in the larger models B or C. Comparing human H3-human 
α2-6 with avian Gln226Leu H3-human α2-6, the former 
has  25.5-27.3  kcal/mol  larger  s-IFIEs  of  the  model  A 
range (Table 6; entries 1 and 11, 5 and 15). The energy 
difference decreases in comparison with corresponding of 
the 13Å radius range (Table 6; entries 2 and 12, 6 and 16).  
 
 
CONCLUSIONS 
 
Influenza  viral  H3  HA1  domains  in  complex  with 
Neu5Acα(2-3  and  2-6)Gal  analogs  were  studied  at  the 
FMO-MP2/6-31G level. Avian H3 bound to the avian-type 
receptor  Neu5Acα(2-3)Gal  15.3  to  16.5  kcal/mol  more 
strongly  than  to  the  human-type  receptor  Neu5Acα(2-
6)Gal. Sialoside binding domain Arg(Ile)62-Gly263 (202 
amino  acids,  avian  H3;  Arg62,  human  H3;  Ile62)  was 
enough  size  for  estimating  the  binding  energy  of  HA1 
monomer-Neu5Ac-Gal  disaccharide  complex.  We 
analyzed  IFIEs  between  the  Neu5Acα(2-3/6)Gal  and 
amino acid residues on H3 HA1 to find that it is important 
to evaluate the IFIEs of amino acid residues within 13Å 
radius  around  Neu5Ac-Gal  coupled  with  more  accurate 
evaluation  of long-range electrostatic interactions.  These 
results demonstrated the relationships between the model 
sizes of HA1-sialoside complexes, their binding energies 
and sum of the IFIEs, then gave some guidance toward in 
silico  prediction  studies  about  HA-sialosides  binding 
properties. 
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HA: Hemagglutinin 
Neu5Ac: α-N-acetyl-D-neuraminic acid 
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FMO: Fragment molecular orbital 
MP2: Second-order Møller–Plesset perturbation 
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